You are here: Industry Insights > Janssen Pharmaceutical

News List

Catalent, J&J Announce COVID-19 Vaccine Candidate Manufacturing Agreement americanpharmaceuticalreview
May 06, 2020
Catalent has announced a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby Catalent’s Biologics business unit will accelerate availability of manufacturing capacity ...
Catalent, J&J Enter Mfg. Pact for COVID-19 Vax Candidate contractpharma
April 30, 2020
Includes joint investment and tech transfer to prepare for rapid scale-up and cGMP commercial manufacturing at Catalent's Bloomington facility.
Janssen Submits sBLA for SIMPONI ARIA for Juvenile Arthritis americanpharmaceuticalreview
April 26, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of two supplemental Biologics License Applications (sBLA).
J&J selects Emergent BioSolutions for Covid-19 vaccine manufacturing pharmaceutical-technology
April 26, 2020
Johnson & Johnson (J&J) subsidiary Janssen Pharmaceutical has signed an agreement with Emergent BioSolutions for manufacturing services for its lead investigational Covid-19 vaccine candidate.
Fate Therapeutics Announces Cancer Immunotherapies Collaboration americanpharmaceuticalreview
April 09, 2020
Fate Therapeutics announced a global collaboration and option agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
ViiV Healthcare, Janssen get Canadian approval for Cabenuva pharmaceutical-technology
March 24, 2020
ViiV Healthcare and Janssen Pharmaceutical have announced the Health Canada approval of Cabenuva as a once-monthly, long-acting therapy for adults with HIV-1 infection.
J&J’s Janssen and BIDMC team up on Covid-19 vaccine pharmaceutical-technology
March 17, 2020
Johnson & Johnson (J&J) subsidiary Janssen Pharmaceutical has partnered with the Beth Israel Deaconess Medical Center (BIDMC) to advance Covid-19 vaccine development.
Janssen submits MAA to EMA for esketamine nasal spray pharmaceutical-technology
October 12, 2018
Johnson & Johnson’s Janssen Pharmaceutical Companies has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for its esketamine nasal spray.
Janssen Announces Mixed Results of Esketamine Nasal Spray Study americanpharmaceuticalreview
September 25, 2018
Janssen Pharmaceutical announced results from a Phase 3 clinical study of the investigational product esketamine nasal spray in patients with treatment-resistant depression.